A Method to Study the Epigenetic Chromatin States of Rare Hematopoietic Stem and Progenitor Cells; MiniChIP–Chip by Holger Weishaupt & Joanne L. Attema
A Method to Study the Epigenetic Chromatin States
of Rare Hematopoietic Stem and Progenitor Cells;
MiniChIP–Chip
Holger Weishaupt & Joanne L. Attema
Received: 25 March 2010 /Accepted: 21 April 2010 /Published online: 15 May 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Dynamic chromatin structure is a fundamental
property of gene transcriptional regulation, and has emerged
as a critical modulator of physiological processes during
cellular differentiation and development. Analysis of chro-
matin structure using molecular biology and biochemical
assays in rare somatic stem and progenitor cells is key for
understanding these processes but poses a great challenge
because of their reliance on millions of cells. Through the
development of a miniaturized genome-scale chromatin
immunoprecipitation method (miniChIP–chip), we have
documented the genome-wide chromatin states of low
abundant populations that comprise hematopoietic stem cells
and immediate progeny residing in murine bone marrow. In
this report, we describe the miniChIP methodology that can
be used for increasing an understanding of the epigenetic
mechanisms underlying hematopoietic stem and progenitor
cell function. Application of this method will reveal the
contribution of dynamic chromatin structure in regulating the
function of other somatic stem cell populations, and how this
process becomes perturbed in pathological conditions.
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1 Introduction
A unique and defining property for any stem cell
population is intrinsic self-renewal throughout the process
of cell division, whilst maintaining the capacity to form
multiple differentiated and mature cell types over the lifetime
of an organism. Stem cells undergo dramatic changes in
morphology, cell cycle status and gene expression during
differentiation into specialized progenitor subsets. Such
alterations are proposed to result from chromatin reorganiza-
tion of the genome, allowing for the establishment and
maintenance of lineage-specific transcriptional networks [1,
2]. Therefore, cellular differentiation can be viewed as a
product of heritable chromatin states, which in turn, are
induced and maintained by specific epigenetic chromatin
modifications [3].
Chromatin structure defines the higher order structure by
which DNA is organized within the cell nucleus [4]. It
consists of a chain of nucleosomes, representing about
146–147 bp of DNA wrapped around a core of histone
octamers [5]. The precise degree of nucleosome compac-
tion at genomic regions influences the accessibility of
transcription factor binding to gene promoters and
enhancer regions critical for transcriptional regulation
[6]. Accordingly, genomic regions are packaged into
euchromatin, which forms a relaxed structure of large
genomic distances between nucleosomes, or a higher
degree of DNA compaction known as heterochromatin
[7]. Euchromatin is also referred to as active chromatin
and is linked to actively transcribed regions of the
genome, while genes located in heterochromatin (inactive
chromatin) are usually transcriptionally silent.
In mammals, the most studied epigenetic chromatin
modifications are DNA methylation and covalent modifi-
cations at the N-terminal tails of histone proteins [8, 9].
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DNA cytosine methylation, as mediated by the DNA
methyltransferases, is thus far the only epigenetic mecha-
nism known to directly modify DNA [10, 11]. DNA
methylation occurs mainly on cytosine–phosphate–guanine
dinucleotides that are associated with transcriptionally
inactive heterochromatic regions to mediate stable gene
silencing. Histone proteins including their N-terminal tails
regions are subject to a variety of different post translational
modifications, including methylation, acetylation, phos-
phorylation, ubiquitylation, sumoylation, ADP ribosylation,
glycosylation, biotinylation, and carbonylation [12]. Unlike
DNA methylation, which has been linked gene silencing,
these diverse histone modifications show differential
patterns of activating and silencing effects on gene
transcription. For example, histone acetylation is almost
entirely associated with gene activation, while lysine
methylation can lead to both gene activation and silencing
depending on the modified lysine residue and the degree of
methylation (mono-, di-, or trimethylation). To date, over
100 possible histone modifications have been identified.
Accumulating evidence reveals that most histones are
simultaneously modified by a combination of different
modifications, and directly supports the histone code
hypothesis [13–15]. Recent efforts in deciphering this
highly complex code in cellular differentiation are beginning
to shed light on the molecular mechanisms of lineage
commitment and differentiation potential during development
[16–20].
A gold standard approach for the investigation of
epigenetic chromatin states is the chromatin immunopre-
cipitation (ChIP) assay. ChIP is a powerful method that
directly permits the measurement of in vivo DNA–protein
interactions, through the use of antibodies targeted against
specific DNA-associated proteins and thus enriching for the
bound DNA fragments [21, 22]. Recently, ChIP has been
combined with microarray (ChIP–chip) and high through-
put sequencing (ChIP–Seq) technologies to perform
genome-wide analysis of transcription factor and histone
modification association at genomic regions in a wide range
of cell types including embryonic and adult stem cell
populations [8, 20, 23–25]. However, traditional ChIP
protocols require a large amount of cells for starting
material (typically >1×107 cells), which has frequently
limited such analyses to primary cells differentiated in
culture, cell lines, whole tissues, and primary cells from in
vivo sources.
To overcome this technical hindrance, we and others
have recently developed modified ChIP assays allowing for
loci-specific and global-based analyses to be performed
with cell numbers ranging from 100,000 to as few as 1,000
cells [26–28]. These technical developments have proven to
be critical for positioning this method into the cell number
range of primary stem and progenitor cell populations that
normally occur in vivo. Typically, primary stem cell
populations responsible for maintaining tissues and organs
occur at a very low frequency. Our method that we refer to
as miniChIP–chip has enabled for the analysis of 10,000
primary highly purified hematopoietic stem cell popula-
tions, which are present in the bone marrow at a frequency
of 0.0001% [28]. Here we describe the detailed methods to
investigate the chromatin states of murine hematopoietic
stem cells (HSCs), early progenitors, and the bioinformatics
approaches used to identify novel regulators of hematopoiesis
with miniChIP–chip and gene expression microarrays. The
miniChIP–chip technology described in this method article
could be applied in studies that aim to investigate the
chromatin states of other somatic stem cell compartments
during normal physiology, rare primary cell populations
obtained from pathological tissues, as well as cell suspensions
obtained frommodel organisms such as zebrafish, fruitfly, and
nematodes.
2 Materials and Methods
2.1 Reagents and Equipment
Hanks buffered salt solution (HBSS 14175-053), Dulbecco’s
modified eagle medium (DMEM #31966-021), Dulbecco’s
phosphate-buffered saline (DPBS 14190-094) were purchased
from Gibco. Fetal calf serum (FCS) was purchased from
Hyclone Laboratories. CD117 (ckit) microbeads (130-091-
224) was purchased from Miltenyi Biotech. Dynabeads®
Protein A (100.02D), phenol/chloroform/isoamyl alcohol
(15593-049) and SYBR® GreenER mastermix (11761-500),
Superscript III First strand synthesis system (18080-051) and
1 mg/mL Propidium Iodide (Molecular Probes, P3566) were
purchased from Invitrogen. Complete protease inhibitor
cocktail (PIC, 11697498001) and Proteinase K
(03115828001) were purchased from Roche. Thirty-seven
percent formaldehyde solution (F8775), β-mercaptoethanol
(63689), and GenomePlex® whole genome amplification kits
(WGA2 and WGA4) were purchased from Sigma Aldrich.
Linear acylamide (AM9520), glycogen (AM9510), and
DNaseI (AM2222) were purchased from Ambion. ChIP
antibodies were purchased from the following companies,
anti-H3K4me3 (Upstate MC315 and Abcam ab8580); anti-
H3K79me2 (Upstate NL59); anti-H3K27me3 (Abcam 07-
499); anti-H3K9me3 (Abcam ab8898); and anti-PolII (Active
Motif 39097). Sterile barrier tips with low retention surface
were purchased from CLP Neptune (BT1000, BT200, BT20,
and BT10XL). Eppendorf tubes (1.5 ml, maximum recovery
MCT-150-LC) were purchased from Axygen, whereas 0.2 ml
PCR tubes were purchased from Sarstedt (72.737.002). A
sonication water bath, Bioruptor® (UCD-200), was purchased
from Diagenode.
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2.2 Isolation of Primary Hematopoietic Cells
Murine bone marrow was harvested from the two
femurs, tibias, and hips of 10–12-week-old C57Bl/6
mice following consent from the Lund University ethics
committee. Bone marrow cells (BMC) were harvested by
crushing bones into 10 ml of DPBS containing 2% FCS
(DPBS/FCS). Harvested BMCs were filtered through
70 μM cell strainers (BD falcon) into 50 ml tubes. Bone
fragments were rinsed with an additional 10 ml of
DPBS/FCS, pooled into 50 ml tubes, and centrifuged at
1,200 rpm (300 rcf) for 10 min at 4°C. The supernatant
was discarded and pellets were gently resuspended in
10 ml of DPBS/FCS. The cell suspension was filtered
through new 70 μM cell strainers into new 50 ml tubes,
and centrifuged at 1,200 rpm (300 rcf) for 10 min at 4°
C. The supernatant was removed and the resultant BMC
pellet was gently resuspended in 100 μl of DPBS/FCS
per mouse ready for c-kit enrichment. HSCs, MPPs, and
PreMegEs were positively selected using c-kit conjugated
magnetic beads (Miltenyi, Germany) according to manufac-
turer’s procedures except that 3.5 μl of the bead slurry per
mouse was used, and ckit-bead incubation was performed on
ice for 30min. Following positive selection, cells were stained
in 0.5 ml of DPBS/FCS with directly conjugated antibodies in
the dark for 30 min on ice. The following antibodies were
used; anti-Sca-1-Pacific Blue (D7, Biolegend), anti-c-kit-
APC/AL780 (2B8, eBioscience), anti-Slamf1-APC (CD150;
TC15-12F12.2, Biolegend), anti-CD41-FITC (MWReg30;
Becton Dickinson), anti-CD105-PeCy7 (MJ7/18 eBio-
science), anti-Flt3-PE (A2F10, eBioscience), and the lineage
antibodies against anti-CD4 (GK1.5), anti-CD8 (53–6.7),
anti-B220 (RA3-6B2), anti-Gr1 (RB6-8C5), anti-Mac1
(M1/70), anti-Ter119 (Ter119) directly conjugated to
PECy5 or indirectly to QD605 using biotin/streptavidin
conjugation. Anti-CD48-FITC (HM48-1 Biolegend) anti-
bodies were used in place of anti-CD41-FITC when
performing HSC and MPP analysis as previously
described [29]. Propidium iodide was used to discriminate
dead cells (1 μg/ml in DPBS/FCS). Cells were maintained
on ice when possible through all procedures and were
sorted into maximum recovery 1.5 ml Eppendorf tubes
(Axygen) using the single sort mode on a FACS Aria cell
sorter (Becton Dickinson). Post-sorting reanalysis routinely
showed >95% purity. All flow cytometry and FACS data were
analyzed with FlowJo software (Treestar, Ashland, OR).
2.3 10,000 Cell MiniChIP Assay
The 10,000 cell miniaturized chromatin immunoprecipitation
qPCR (miniChIP–qPCR) method was established from
previously described protocols [30, 31]. It was critical that
each 100 μl lysate represented 10,000 cells otherwise the
assay showed variation between replicate experiments. Low
retention barrier tips and Eppendorf tubes were used in all
steps. Careful pipetting of solutions was employed through-
out, and the pipetting of solutions up and down into reactions
was avoided. The procedure was conducted in a time
efficient manner without long breaks between the steps.
The concentrated stocks of buffers (e.g., 1 M Tris, 0.5 M
EDTA, 5 M NaCl, 10% sodium dodecyl sulfate (SDS)) were
autoclaved and stored at room temperature. The ChIP buffers
were conveniently made in sterile 50 ml Falcon tubes and
were 0.2 μM filter sterilized and subsequently stored at 4°C.
All steps were performed on ice or in a cold room unless
otherwise stated. The following procedure outlines a method
for processing one ChIP reaction comprising 10,000 cells.
This procedure was scaled up to 50,000, 80,000, or 100,000
cells at the formaldehyde crosslinking step depending on the
experimental design (see Step-wise Protocol for a miniChIP
method that describes an experiment starting with 30,000
cells).
Briefly, 10,000 primary cells were crossed-linked in a final
concentration of 0.1% formaldehyde in 1 ml of DMEM
containing 10% FCS at room temperature for 10 min and
washed once with ice-cold HBSS containing protease
inhibitor cocktail (HBSS/PIC) and stored at −80°C. Ten
thousand cross-linked cells were thawed on ice and lysed in
25μl Lysis buffer (10 mMTris pH 7.5/1 mMEDTA/1% SDS)
for 5 min, then diluted with 75μl of HBSS/PIC and the 100 μl
volume was sonicated for five cycles of 30 s with a 30 s rest
period in between cycles (Bioruptor® Diagenode). PIC was
used in all buffers throughout the procedure. The sonicated
chromatin was microcentrifuged for 5 min at 13,000 rpm
(17,000 rcf) at 4°C to remove precipitated SDS and 120 μl
of 2× RIPA buffer (20 mM Tris pH 7.5/2 mM EDTA/2%
Triton X-100/0.1% SDS/0.2% sodium deoxycholate/200 mM
NaCl) was added to recovered supernatants. A 1/10
volume (20 μl) was removed for input control. ChIP-
qualified antibodies were added to the sonicated chro-
matin and incubated at 4°C for 2 h. The amounts of
antibodies were empirically determined in antibody
titration experiments (Figs. 2, S1, S2). This step was
carried out up to 16 h depending on the efficiency of the
antibody. However, prolonged incubation times increased
non-specific antibody binding and chromatin degradation,
and were generally avoided.
Following antibody incubation, 10 μl of protein A or G
Dynabeads® magnetic beads (Dynal, Invitrogen) previously
washed in 1× RIPA buffer were added and incubated for an
additional 2 h at 4°C. The bead–protein complexes were
washed three times with 100 μl of 1× RIPA buffer (10 mM
Tris pH 7.5/1 mM EDTA/1%Triton X-100/0.1% SDS/0.1%
sodiumdeoxycholate/100 mM NaCl) and once with 100 μl
of TE (10 mM Tris pH 7.5/10 mM EDTA) buffer using a
magnetic rack to collect the beads. The genomic DNA was
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then eluted for 2 h at 65°C in 300 µl of Elution Buffer (20 mM
Tris pH 7.5/5 mM EDTA/50 mM NaCl/1% SDS/50 µg/ml
proteinase K) using a shaking Eppendorf Thermomixer
(1,300 rpm). Genomic DNA was recovered into new tubes
and purified using phenol/chloroform extraction (300 µl of
phenol/chloroform/isoamyl alcohol) and subsequent ethanol
precipitation (800 µl of 97% ethanol) using linear acrylamide
and glycogen carriers (10 µg of each). Following centrifuga-
tion (13,000 rpm (17,000 rcf) for 20 min at 4°C) and 70%
ethanol rinse with 400 µl (13,000 rpm (17,000 rcf) for 10 min
at 4°C), genomic DNA pellets were air dried and resuspended
in 24 µl T10E0.1 (10 mM Tris pH 7.5/0.1 mM EDTA) buffer,
and 1 µl was used in each SYBR green qPCR reaction with
gene-specific primers. This enabled 24 individual qPCR
reactions or eight genomic regions analyzed in triplicate PCR
reactions. Real-time PCR reactions were performed in a
BioRad MyiQ sequence detection system using the 2×
SYBR green master mix according to manufacturer’s
instructions (Invitrogen). Enrichment of histone modifica-
tions and PolII at genomic regions were expressed as %
input using the formula; % (ChIP/total input)=2^[(Ct(ChIP)
−Ct(input)×DF)]×100%. This calculation was determined
using equally efficient SYBR green qPCR primer sets as
previously described [28].
2.4 10,000 Cell MiniChIP–Chip Technology
The ChIP DNA was prepared as described in the
miniChIP–qPCR protocol above except that the DNA
pellets were dissolved in 10 µl of T10E0.1 (10 mM Tris
pH 7.5/0.1 mM EDTA) buffer. An entire ChIP sample was
subjected to whole genome amplification (WGA) using
the WGA4 kit (Sigma Aldrich) using 0.2 ml PCR tubes.
Note that the cell lysis and DNA fragmentation steps were
omitted and the protocol started at Step 6 of the WGA4
procedure. A matching number of input samples were
amplified to cover the number of amplified ChIP DNA
samples for array analysis. WGA lead to the production of
∼10 µg of amplified ChIP and input DNA samples. Prior
to array analysis, sample integrity was confirmed using
NanoDrop spectrophotometer and qPCR surveys of
positive and negative control genomic regions was con-
ducted. The NimbleGen HD2 Hx.1 delux promoter tiling
arrays of ∼22,000 RefSeq gene promoters represented in
the mouse genome were used for array analysis of
amplified miniChIP DNA. Microarray hybridization was
performed by NimbleGen Service Facility (Iceland)
according to the manufacturer’s procedures. Raw and
processed data for the miniChIP–chip experiments can be
found under accession number GSE18737 super series in
the NCBI Gene Expression Omnibus. Bioinformatics
scripts used for the data analysis can be obtained by
contacting the authors.
2.5 Quantitative RT-PCR Analysis
For quantitative RT-PCR (qRT-PCR), approximately
5,000–10,000 purified primary hematopoietic cells were
sorted directly into 350 µl of RLT buffer containing
3.5 µl of β-mercaptoethanol (RNeasy micro kit, Qiagen).
Samples were maintained on ice during the sorting
process, mixed by manual agitation, and immediately
snap frozen on dry ice and stored at −80°C until further
processing. Total RNA was isolated using an RNeasy
micro kit (Qiagen) from purified primary hematopoietic
cells using on-column DNaseI treatment according to the
manufacturer’s instructions. The resultant volume of
RNA samples in “EB buffer” following column elution
was 10 µl. The samples were additionally digested with
1 µl DNaseI and 1 µl of 10× DNase1 reaction buffer
(Ambion) for 20 min at 37°C to remove genomic DNA.
DNaseI was inactivated by incubating samples at 65°C
for 10 min. The sample (12 µl) was then used for
reverse-transcription using random hexamers according
to the manufacturer’s instructions (SuperScript III RT-
PCR system, Invitrogen). The qRT-PCR reactions were
performed with 500 cell equivalents of RNA and gene-
specific primers in a BioRad MyiQ sequence detection
system using the 2× SYBR green master mix according
to manufacturer’s instructions (Invitrogen).
2.6 Affymetrix Gene Expression Experiments
For Affymetrix gene expression microarray experiments,
approximately 5,000–10,000 purified primary hematopoietic
cells were sorted directly into 350 µl of RLT buffer containing
3.5 µl of β-mercaptoethanol (RNeasy micro kit, Qiagen).
Samples were maintained on ice during the sorting process,
mixed by manual agitation, and immediately snap frozen on
dry ice and stored at −80°C until further processing. RNAwas
extracted from purified primary hematopoietic cells using
the RNeasy micro kit (Qiagen) using on-column DNaseI
treatment according to the manufacturer’s instructions.
The resultant volume of RNA samples in “EB buffer”
following column elution was 10 µl. Following quality
control assessment using Bioanalyser analysis (Agilent),
approximately 10 ng of each RNA sample was subjected
to rounds of RNA amplification using the Affymetrix
sample labeling kit according to the manufacturer’s
instructions. Samples were processed (labeling, hybrid-
ization, washing, scanning) using the Affymetrix Mus
musculus 430 2.0 arrays. Array processing was per-
formed in the SciBlue service Facility (Lund University,
Sweden). Raw and processed data for the Affymetrix
microarray experiments can be found under accession
number GSE18737 super series in the NCBI Gene
Expression Omnibus.
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3 Results and Discussion
3.1 MiniChIP–qPCR Assays Based on 10,000 Cells
We have established a streamlined miniChIP–qPCR method
that enables for the reproducible analysis of 10,000 cells
[28, 30, 32]. As we reported recently, this was a refinement
of our previously described miniChIP–qPCR method,
which allowed histone modifications to be identified at
selected genes using 50,000 cells [30]. Thus, we made
further modifications to enable rapid genome-scale analysis
using 10,000 cells. Further reducing the cell number require-
ments of the miniChIP method was critical in order to study
the unusually small numbers of hematopoietic stem cells
present in adult murine bone marrow (∼2,000 cells/two
femurs, tibias, and hip bones per mouse). During the
development of this method, two independent reports
demonstrated μChIP and microChIP using 1,000 and
10,000 cells, respectively, thus providing additional
support for scaled ChIP–chip methods [26, 27, 33]. In
this following section, we discuss the types of reagents
and quality controls required for effective implementation
of miniChIP–qPCR assays into the research laboratory.
In order to scale down our recently described
miniChIP–qPCR method from 50,000 cells to 10,000
cells, new reagents and simplified steps were intro-
duced. These refinements lead to a miniChIP–qPCR
method that was short, easy, and reliable for use with
10,000 cells per experimental condition (1 day from
cells to qPCR analysis of miniChIP DNA; Fig. 1;
Materials and Methods) [32]. The new assay components
included low retention tubes and tips (Axygen), protein
A/G magnetic beads (Dynal), water bath sonication, one-
step cell lysis, reduced reaction volumes, dilutions,
incubation times, and immune complex wash steps. The
concentration of formaldehyde used for protein–DNA
crosslinking was reduced tenfold compared to other
methods that typically employ 1% formaldehyde [26,
33]. We found that protein–DNA crosslinking with 0.1%
formaldehyde reduced the false positive signals at
genomic regions, increased genomic DNA recovery
following reversal of crosslinks/DNA purification steps
and improved signal to noise ratio (data not shown). The
use of a single-step cell lysis approach was critical for
further minimizing sample loss. This was in contrast to
other scaled methods, which comprised at least two lysis
steps for cellular extraction and subsequent lysis [26, 33]
thereby increasing sample loss. Our method relied on a
single incubation of cell pellets with lysis buffer, followed
by one tube change in preparation for chromatin shearing
using a water bath sonicator. This simplified lysis step
reduced sample handling and loss, which would impact
on ChIP efficiencies.
The sonication step was a critical component of our
ChIP method, and cycle conditions were optimized for each
cell quantity used. Sonication analysis using 10,000 cells
presented a challenge due to the low amount of DNA
recovered for subsequent analysis using agarose gels.
Therefore, we processed at least three replicate 10,000 cell
reactions for each sonication cycle number tested, and
pooled the reactions prior to the DNA recovery steps
(Figure S1). This enabled visualization of the sheared DNA
on agarose gels as previously described [26]. The use of a
sonication bath (Diagenode) was used when dealing with
small numbers of cells. This device supported sonication of
small reaction volumes by eliminating foaming. In our
method, the sonication of 10,000 cells was performed in
100 μl, which comprised 25 μl of lysis buffer and 75 μl of
Hanks Buffered Salt Solution (HBBS). Dilution of the cell
lysate with HBBS reduced the sodium dodecyl sulfate
concentration to 0.25%, which allowed for optimal sonica-
tion and immunoprecipitation reaction conditions. Impor-
tantly, a twofold dilution with 2XRIPA buffer could be
performed instead of tenfold dilution that has been described
in the conventional Upstate/Millipore Protocol (cat no. 17-
295) as well as other scaled methods [26, 33]. Thus, we
could perform a highly efficient immunoprecipitation
reaction in 200 μl and in other words, tenfold less volume
compared to other conventional and scaled methods [34].
The success of miniChIP assays critically depended on the
quality assessment of antibodies used during the chromatin
immunoprecipitation step. Figure 2 shows a comparison of
anti-H3K4me3 antibody in standard ChIP–qPCR (1×106
cells per reaction) and miniChIP–qPCR (10,000 cells per
reaction) assays. Using standard and miniChIP, the highest
enrichment value obtained for anti-H3K4me3 was observed
with 0.25 and 0.5 μg, respectively, at the transcriptionally
active βactin promoter but not the silent albumin promoter
(Fig. 2a). However, the optimal amounts of antibody lead to
a high degree of non-specific false positive enrichment at the
albumin promoter in miniChIP but not the standard assay
(Fig. 2b). Titration analysis of anti-H3K4me3 revealed that
an optimal signal to noise ratio was achieved in miniChIP
using twofold less antibody. False positive enrichment at
numerous genomic regions occurred when using higher
concentrations of ChIP-qualified antibodies specifically in
miniChIP assays (data not shown). This probably related to
the antibody type and the purification method used since
anti-H3K4me3 and anti-H3K27me3 showed this behavior
but not anti-H3K36me3 and anti-H3K9me3. The possible
cause remains unclear, but could most likely result from using
significantly less chromatin in miniChIP reactions compared
to the standard assay. Nonetheless, this result emphasized the
importance of performing broad titrations of antibodies in
order to assess their performance in the modified miniChIP
assays compared to the standard protocol.
MiniChIP–Chip Technology Based on 10,000 Cells 5
Fig. 1 Technical pipeline for the miniChIP–chip technology platform
using 10,000 cells. The flowchart depicts the three main methodical
phases of the miniChIP–chip procedure: sample processing, data
preparation, and data analysis. Detailed steps of the data preparation
phase (A–E) is indicated including a visual depiction of the array data
and possible quality controls (QC). The representative data in A–E
was obtained from miniChIP–chip investigations of H3K4me3
associated with the Cxcr4 locus in murine hematopoietic stem cells
(phenotypically defined by fluorescence-activated cell sorting as
lineage−/lo, ckit+, Sca1+, CD150+, Flk2/Flt3− [28])
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Careful screening of antibodies from different companies
increased the likelihood of finding an antibody suitable for use
in the miniChIP assays. For example, anti-H3K27me3 was
sourced from Active Motif (AM174), Millipore (07-499), and
Abcam (ab6002). As shown previously and in Figure S2,
H3K27me3 associated with the p16Ink4a and Myt-1 loci in
early passage murine embryonic fibroblasts (MEFs) [32]. By
contrast, the promoter regions of GAPDH, βactin, and
Cnpy3 provided excellent negative controls since they were
actively transcribed in MEFs and thus not subjected to
H3K27me3-mediated silencing. Direct comparison of the
three commercially available anti-H3K27me3 antibodies in
miniChIP–qPCR highlighted the importance of performing a
broad titration range in order to accurately assess antibody
quality (Figure S2). We found that the H3K27me3 antibodies
from Millipore and Abcam showed improved specificity and
reduced signal-to-noise ratios compared to the Active Motif
source. Based on these observations, the Abcam and
Millipore anti-H3K27me3 were selected for their use in
subsequent experiments [28, 32].
Another important parameter of miniChIP setup was the
selection of genomic loci that accurately reported on reagent
quality. Genomic loci that are associated with similar
enrichment profiles of histone modifications regardless of
cell type were specifically chosen for this analysis. Thus, for
the assessment of activating histone modifications, we took
advantage of the ubiquitously expressed housekeeping genes,
GAPDH, Cnpy3, and βactin. For example, the GAPDH
promoter and exon regions were associated with the activating
histone modifications H3K4me3, H3K36me3, H3ac, and
H3K79me2, as well as PolII. These histone modifications
showed a distinct distribution pattern across the GAPDH gene
consistent with previous genome-wide ChIP–chip and ChIP–
seq analyses [16, 35, 36]. H3K4me3 enrichment was
observed in close proximity to the transcriptional start sites
(TSS) and characterized by a narrow trough roughly at the
TSS with highest enrichment levels localized to either side
(Fig. 3a). By contrast, the mono- and di-methylation states of
H3K4 showed highest enrichment up and downstream to the
TSS and revealed an overall reciprocal enrichment pattern
compared to H3K4me3. Two marks associated with tran-
scriptional elongation, H3K79me2 and H3K36me3, revealed
highest enrichment levels in the GAPDH gene body
(Fig. 3b). A similar trend was noted for the elongating
polymerase II (PolII) using antibodies directed against the
serine residue 5 of PolII (data not shown). While the GAPDH
gene provided a reliable negative control for the assessment of
H3K9me3 (and H3K27me3) silencing histone modifications,
the selection of ubiquitous positive controls for H3K9me3
was more challenging. However, we have found that the
p16Ink4a and Pax5 promoters provide reliable controls in
early passage MEFs (Figure S3).
To our knowledge, only two other laboratories have
reported the use of miniaturized scaled ChIP assays in loci-
specific and global microarray-based surveys [26, 27]. The
technical difficulties and multiple steps associated with this
method could account for why many laboratories have failed
to successfully implement this technology. Thus, steps such
as sonication optimization, antibody titrations, and the
analysis of appropriate genomic loci for antibody testing,
as well as the use of high recovery, low retention plastics
(Eppendorf tubes and filtered pipette tips) should be
carefully monitored. Our successful implementation of
miniChIP was also reliant on the use of strict molecular
biology laboratory skills, faithful recapitulation of the
method, use of calibrated and clean pipettes, careful pipetting
techniques, correct storage of reagents, regular quality
control testing, and maintenance of ultra clean workspaces.
3.2 Global MiniChIP–Chip Technology
MiniChIP–qPCR was highly effective at resolving small
numbers of cells. However, this approach became limited in
Fig. 2 Titration analysis of an anti-H3K4me3 antibody in standard
and scaled miniChIP assays. Assessment of the anti-H3K4me3
antibody (Upstate 04-745) in standard ChIP (a) and miniChIP (b)
assays using the βactin and albumin promoters across a titration range
of 1–0.05 μg. Standard and miniChIP assays were optimized for the
analysis of 1×106 and 10,000 cells per reaction, respectively.
H3K4me3 enrichment is represented as % input at gene promoters
(y-axis) obtained from the murine embryonic fibroblasts. % input was
determined as described in “Materials and Methods”, and was used for
the analysis of ChIP–qPCR data in all subsequent figures. Low
background signals were detected with the IgG control sera at both
βactin and albumin promoters. Error bars represent the standard
deviation (±SD) of at least three independent ChIP assays
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scope when performing experiments that aimed to identify
histone modification profiles at numerous genomic loci or
genome wide. This was, in part, explained by the low
amounts of DNA recovered from 10,000 cells, which
permitted the analysis of about 10 different genomic
regions. The recent development of DNA amplification
methods suited for low quantities of genomic DNA enabled
the coupling of miniChIP assays to promoter tiling arrays in
order to increase target identification. Most recently, we and
others have described the use of whole genome amplifica-
tion kits (Sigma WGA4) optimized for low concentrations
of ChIP DNA and NimbleGen promoter tiling microarrays
in order to develop miniaturized scaled ChIP–chip studies
[26–28]. Our most recent study was based on the analysis
of data obtained from 72 separate NimbleGen high density,
2.1 million feature promoter tiling arrays, thus enabling the
investigation of five different histone modifications and
PolII (6 ChIP conditions) in four primary cell types, each
performed in triplicate [28]. In this section, we describe
detailed computational methods and quality control steps
that facilitated our investigation of epigenetic chromatin
modifications during cell fate decisions of murine HSCs in
bone marrow using miniChIP–chip.
The NimbleGen promoter tiling array platform com-
prised two-color arrays and were subject to non-biological
variations including dye-bias resulting from different
labeling efficiencies of the Cy3 and Cy5 dyes [37]. These
variations lead to an intermixture of signals from enriched
and unenriched samples and therefore caused an increase in
background noise that hindered the identification of
enriched regions. Additional variations resulted from the
array processing itself, especially when the array number
was too high to be processed in a single batch experiment.
In our study, since the 72 arrays were processed in four
separate batches, we anticipated differences in handling and
use of multiple reagent lots. Such variations potentially
affected the overall range of signals between arrays and
therefore reduced sample comparability. In order to address
these issues, we began our data analysis with an effective
normalization strategy. For this purpose, a two-step
Fig. 3 The spatial distribution
of H3K4me3 across the
GAPDH gene. Using antibodies
specific for H3K4me1,
H3K4me2, H3K4me3,
H3K79me2, or H3K36me3, the
enrichment levels (% input) of
these different histone modifi-
cations were determined in
MEFs at the GAPDH transcrip-
tional start site (TSS) and gene
body. a The distribution profiles
of H3K4me1, H3K4me2, and
H3K4me3 at GAPDH. b The
distribution profiles of
H3K79me2 and H3K36me3 at
GAPDH. In both figures, the
genomic region analyzed by
qPCR is shown on the x-axis
and is designated as kilobase
(kb) distance from the TSS.
Error bars represent the stan-
dard deviation (±SD) of three
independent ChIP assays
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normalization protocol was implemented (Fig. 1 (A, B)). In
the first step, the raw data was normalized using the MA2C
software designed especially for “within-array” normaliza-
tion of NimbleGen ChIP–chip data (Fig. 1 (A)) [37, 38].
The second step comprised a quantile normalization
approach (Fig. 1 (B)) [36, 39]. This method allowed for
“between array” normalization, which aimed to enhance the
comparability of signal ranges between replicate arrays by
defining the final intensity of probes within a specific
quantile as the average value of this quantile. Applying the
above steps to the array data and subsequently averaging
replicate intensities (Fig. 1 (C)), histone modification
profiles for the four hematopoietic cell types were derived
and subsequently investigated for their association with
lineage commitment [28].
To confirm that this protocol produced reliable data and
effectively eliminated any non-biological variations or
technical artifacts, we performed exhaustive quality
control confirmations following each normalization step
[28]. Within array normalization was especially important
when dealing with DNA oligonucleotide microarrays. This
method enabled us to determine the extent by which dye-
bias or other non-biological variations had influenced the
raw data. Within array normalization was visually inves-
tigated using M versus A plots, where M was the
difference in log intensity (M ¼ log2 R=Gð Þ; with R and
G as the intensity of the red and green channel,
respectively) and A was the average of the log intensity
values (A ¼ 12 log2 R»Gð Þ) for each probe [40]. In the
absence of any dye-bias, the majority of the data, i.e.,
the unenriched probes, clustered around the horizontal line
M=0, without showing any dependence on the intensity A
[37]. Deviations from this appearance as manifested by
intensity shifts or rotations away from the horizontal line,
were clear indications of non-biological artifacts to the
data, and were corrected using proper data preprocessing.
Accordingly, the MA plots provided a useful tool in
estimating the need for specific data preparation steps as
well as assess and fine-tune the performance of our
normalization strategy (Fig. 1 (A)—QC step, Figure S4).
Following within-array normalization, differences in
data range of the replicate arrays persisted. This was due
to the hybridization process itself, which introduced a shift
in the signal intensity causing the range of signals to be
different between the replicate arrays. Therefore between-
array normalization was employed using a quantile nor-
malization approach. This method resulted in the scaling of
all signals obtained from replicate arrays into the same data
range. Inspecting and comparing the range of signals
between the corresponding arrays using box and whisker
plots directly tested the performance of this normalization
approach (Fig. 1 (B)—QC step). Scatter plots and Pearson
correlation estimates were performed between each pair of
replicates before and after normalization (Fig. 1 (B)—QC
step). Importantly, the quantile normalization strategy was
not used for array data obtained from different cell types.
The strategy removed differences in signals observed across
cell types that resulted from biological changes. Instead,
array comparability was tested through inspection of a
panel of housekeeping genes, which showed highly similar
enrichment profiles across the range of cell types studied
(Bing Ren and Gary Hon, personal communication).
Upon completion of the normalization steps, significantly
enriched regions within the normalized Log2 ChIP/input
ratios against the background of the unenriched sample were
determined (Fig. 1 (D)). In our study, the detection of
enriched regions or “peaks” was performed using the
NimbleScan software v2.1 in accordance with NimbleGen
Systems standard operating procedures [28]. The input data
represented the average of the normalized probe data
obtained from triplicate arrays. NimbleScan peaks were
determined as regions comprising at least four adjacent
probes that showed a Log2 intensity above a cut-off value of
90% down to 15% of a theoretical maximum enrichment
value. These regions were identified using a sliding window
of 500 base pairs width. Following peak finding, the ratio
data was permutated in order to calculate false discovery
rates (FDR) for the observed peaks. To limit the drawing
of conclusions from a dataset comprising of possible
false positives, only the most stringent peaks were
considered that showed a FDR ≤0.05. However, less
stringent peaks, as indicated by 0.05≥FDR≤0.2, were
included for some quality control analyses, and became
useful when comparing individual loci. For example, we
found that the lower stringent peaks provided insight into
the degree of resolution differences between replicates
due to hybridization and other array processing technical
artifacts [28].
When mapping the identified NimbleScan peaks to anno-
tation tracks, in our case to the NCBI gene tracks (Fig. 1 (E)), a
large proportion of peaks were found in close proximity and
thus matched to a number of different transcriptional start sites
within the overlapping 11.2 kb (−8.2 kb to +3 kb) tiling
regions. Therefore, we sought to obtain a unique association
between single peaks and promoters in order to reduce the
number of false positives. This approach enabled the
allocation of each peak to a single promoter rather than
linking a single peak across numerous promoters, and
potentially leading to false positive and negative data. Since
individual inspection for the unique linkage of peaks and
promoters was not possible in our genome-scale study, we
resolved this by linking each peak to the most proximate TSS
within respective 11.2 kb tiled regions.
In addition, the number of peaks at enriched regions were
often highly variable in that many promoters were found
associated with a varying numbers of peaks, sometimes >15
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peaks per promoter. However, close inspection of the enriched
regions revealed that a high number of peaks was not
indicative of an overall larger enriched region, since a single
broad peak was often found to a span larger genomic region
compared to the multiple smaller peaks. This phenomenon
was likely caused by stochastic variances or processing related
hybridization/labeling issues that introduced random intensity
reductions in one or more probes within the enriched regions.
The NimbleScan peak finding algorithm interpreted these
gaps or signal reductions as unenriched regions. Therefore, a
single enriched region was potentially split into a multitude of
smaller adjacent peaks. Since we were unable to control for
whether these differences in peak variance were biological or
technical related, our analysis was based on present/absent
peak calls rather than peak number in order to identify genes
enriched for specific histone modifications. Thus, a promoter
was defined as being enriched for a histone modification if it
comprised at least one peak of FDR ≤0.05.
To further confirm the NimbleScan peaks, additional
analyses of the NCBI-mapped data were performed. These
included global evaluations of genomic distribution maps.
Histograms were created in order to show the number of
peaks detected at specific genomic distances linked to TSSs
(Fig. 1 (E) QC). In our study, we identified the expected
distribution of histone modifications, which confirmed
previous studies [16, 28]. We employed individual inspec-
tion of loci in order to visualize differences between
replicates and to confirm the correct identification of bound
regions (Fig. 1 (E) QC). The ideal targets for this analysis
included well-characterized promoters for each of the given
histone modifications including housekeeping genes. Ge-
nomic data were routinely confirmed for approximately 12
promoters using ChIP–qPCR and biologically independent
samples (Fig. 1 (E) QC).
The resultant processed miniChIP–chip data was ana-
lyzed according to the requirements of an individual study
design. An initial analysis included the incorporation of
global gene expression data in order to investigate the effect
of histone modifications on gene activation, silencing and
poising. Indeed, our previous analyses revealed a positive
correlation trend for modifications reported as activating in
the literature, while the opposite negative correlation was
true for silencing histone modifications [28]. In Fig. 4, this
analysis was developed further in order to determine the
combinatorial effect of the investigated histone modifica-
tions on gene expression. In this study design, we defined
an arbitrary value to describe the combined effect of
activating and silencing histone modifications and PolII
on gene promoters. We derived “net enrichment” by
calculating for each peak the bound area multiplied by
peak score and then summing the results for all peaks and
conditions, while assigning negative signs to peaks of
silencing histone modifications. Thus we observed high net
values for genes exclusively bound by activating modifica-
tions, negative net values for genes bound only by silencing
modifications and intermediate values for genes with
combinatorial histone modification profiles. When net
enrichment at promoters was related to gene expression, a
high degree of the expected correlation was demonstrated
(Fig. 4a). Accordingly, gene expression was positively
correlated to net enrichment while the opposite negative
correlation was observed for genes lacking expression or
showing expression at low levels. To investigate these trends
in greater detail, the changes in histone modification peak
scores were analyzed in the context of up- or downregulation
of gene expression. For this purpose, the average change in
peak score of the five histone modifications (H3K4me3,
H3ac, H3K79me2, H3K27me3, and H3K9me3) and PolII
over a range of differential gene expression changes between
HSCs and CD4+ T cells was investigated (Fig. 4b). Our
analysis revealed a strong positive correlation with regard to
gene upregulation and peak scores of the activating histone
modifications and PolII. Likewise, a correlative decrease of
the silencing histone modification peak scores was observed
at the upregulated genes confirming the net enrichment
trends (Fig. 4a and b). As expected, the opposite correlation
trends where observed for the downregulated genes. There-
fore, our data revealed that the change in peak score values
was highly proportional to the degree of up- or down-
regulation of gene expression.
4 Summary
The miniChIP–chip approaches described here can be utilized
to identify the chromatin states of primary cell types that are
present as both rare and abundant populations in tissues and
organs across many model organisms. Recent developments
in epigenetic-based technologies, including miniChIP–chip,
will continue to pave the way in expanding our knowledge on
the mechanisms of epigenetic inheritance, gene transcription,
and genomic function in developmental processes and tissue
homeostasis. Epigenetic resolution of rare cell populations
responsible for maintaining a range of pathological conditions
including inflammation and cancer is becoming an achievable
goal for most laboratories. These methods will help to uncover
novel targets in complex biology and disease.
5 Protocols
5.1 Miniaturized Chromatin Immunoprecipitation
(MiniChIP) Assay Based on 10,000 Cells
Notes: It is critical that each reaction volume represents
10,000 cells otherwise the assay will not be reproducible or
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consistent. Low retention barrier tips and Eppendorf tubes
must be used in all steps. Do not pipette up and down when
adding solutions to tubes. The procedure must be
conducted in a time efficient manner without long breaks
between steps. Working stocks of buffers (e.g., 1 M Tris,
0.5 M EDTA, 5 M NaCl, and 10% SDS) should be
autoclaved and stored at room temperature. The ChIP
buffers should be 0.2 μM filtered and stored at 4°C, and
can be conveniently made in sterile 50-ml falcon tubes.
All steps must be performed on ice or cold room unless
otherwise stated.
5.1.1 A. Sonication Optimization
Formaldehyde crosslinking and cell lysis
1. Sort 50,000 cells into 1 ml of DMEM + 10%FBS in an
Eppendorf tube. This number of cells will allow for five
sonication conditions comprising 10,000 cells. For
visualization of sheared DNA from 10,000 cells on
agarose gels, 3×50,000 cell replicates will be required.
We recommend using a primary cell population that is
abundant and easy to isolate using FACS, e.g., CD4+ T
cells from mouse spleen or a passaged cell line.
2. Add 2.7 μl of 37% formaldehyde (0.1% final concen-
tration) and invert tubes immediately two to three times
to ensure complete mixing. Incubate at room tempera-
ture for 10 min with occasional manual agitation.
3. Pellet cells by centrifuging at 2,500 rpm (300 rcf) for
10 min at 4°C.
4. Transfer tubes to ice and remove supernatant.
5. Add 1 ml of ice-cold HBSS containing protease
inhibitor cocktail (HBSS+PIC), and invert the tubes
three to four times to wash cells.
6. Pellet cells by centrifuging at 2,500 rpm (300 rcf) for
10 min at 4°C.
7. Transfer tubes to ice and remove supernatant.
8. For 50,000 cells, add 125 μl of Lysis buffer and 1.25 μl
of PIC (100× stock) so that each 10,000 cell quantity will
be lysed with 25 μl. Do not pipette up and down or
vortex, instead manually agitate the bottom of the
Eppendorf tubes, and allow bubbles to form.
9. Incubate on ice for 5 min to ensure complete lysis.
10. Add 375 μl of HBBS+PIC (5×75 ul) to tubes and mix
by gently inversion four to six times. If the SDS forms a
white cloudy precipitate, place the tubes at room
Fig. 4 Correlation of histone modifications and gene expression. a
Correlation of summarized net enrichment of five histone modifications
(H3K4me3, H3ac, H3K79me2, H3K27me3, and H3K9me3) and PolII
(y-axis) at genes with expression levels of the corresponding ∼23,000
genes (x-axis). Arbitrary values of net enrichment were calculated by
summing the individual features (enriched basepair (bp) area multiplied
by highest peak score) of all histone modifications, while considering
the effect of silencing histone modifications (H3K27me3 and
H3K9me3) as a negative activation, and subsequently normalizing for
the number of activating and silencing histone modifications present at
each promoter. Genes were clustered into bins of 100 genes each. b
Increase of Log2 enrichment scores (y-axis) upon up- or downregulation
of gene expression levels between murine hematopoietic stem cells
(HSC) and splenic CD4+ T cells (T cell) for five histone modifications
(H3K4me3, H3ac, H3K79me2, H3K27me3, and H3K9me3) and PolII
(x-axis). A total of 12 different fold change categories for up- and
downregulation of gene expression is shown (fold changes of 1.5, 2, 2.5,
3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, and 7). The increase in Log2 peak scores for
the histone modifications and PolII was averaged at gene promoters
belonging to each category of fold change in gene expression (y-axis)
R
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temperature for about 2–3 min and mix by gently
tapping the tube until precipitate dissolves. Place directly
on ice and proceed to step 11 immediately. It is important
that aliquots are prepared without SDS precipitation.
11. Aliquot 100 μl (25 μl lysis buffer + 75 μl HBSS+PIC
containing 10,000 cell equivalents) of cell lysate into
new Eppendorf tubes (15 in total).
Sonication optimization
1. Place the tubes into a sonicator water bath unit (Diage-
node) that contains prechilled water to the recommended
volume, and a 2 cm thick layer of ice for cooling. Perform
the sonication using the 30-s on/off cycle program and a
high setting according to the manufacturer’s instructions.
For each cycle, three tubes each comprising a cell lysate
equivalent of 10,000 cells will be processed.
Tube 1: one cycle
Tube 2: three cycles
Tube 3: five cycles
Tube 4: seven cycles
Tube 5: 10 cycles
2. Replenish the 2 cm ice layer to maintain the temper-
ature at 2–8°C during sonication.
3. Remove tubes from the sonicator once the desired number
of cycles has been reached, and place back on ice.
4. Collect the soluble chromatin by centrifugation at
13,000 rpm (17,000 rcf) for 10 min at 4°C. Note that
a tight white pellet will be present following centrifu-
gation. This will comprise precipitated SDS, which
should be avoided when removing the supernatants.
Transfer the supernatants to new Eppendorf tubes and
pool according to cycle number. The pooled volume for
each cycle condition will be 300 μl and there will be
five tubes in total.
5. Add 10 μl of 5 M NaCl and 1 μl of 20 mg/ml of
Proteinase K to each tube.
6. Incubate with mixing at 1,300 rpm 68°C for 2 h using a
thermomixer (Eppendorf).
DNA purification
1. Briefly centrifuge tubes to remove sample from lid
and walls of the tube.
2. Add 300 μl of phenol/chloroform/isoamylalcohol and
mix by vortexing for ∼3 s.
3. Centrifuge samples for 10 min at 13,000 rpm
(17,000 rcf) at room temperature.
4. Transfer the upper aqueous phase (300 μl) into new a
tube.
5. Add 30 μl of 3 M sodium acetate (pH5.2), 2 μl of
linear acrylamide (5 μg/μl stock) and 2 μl of glycogen
(5 μg/μl stock) to the supernatant, and mix by manual
agitation of tubes.
6. Add 800 μl of 97% ethanol (stored at −20°C). Mix
tubes by inversion four to six times and incubate for
∼16 h at −20°C or 1 h at −80°C.
7. Centrifuge the tubes at 13,000 rpm (17,000 rcf) for
20 min at 4°C to collect the precipitated DNA.
8. Remove the supernatant. Add 1 ml of 70% ethanol
(stored at −20°C) and invert the tubes four to six times.
9. Centrifuge the tubes at 13,000 rpm (17,000 rcf) for
20 min at 4°C.
10. Remove the supernatant.
11. Air dry the DNA pellet and resuspend in 20 μl T10E0.1
(10 mM Tris–HCl pH 8.0, 0.1 mM EDTA pH 8.0)
buffer. Store the DNA samples at −20°C.
Agarose gel electrophoresis
1. Run the entire sample (20 μl) onto a 1% agarose gel in
order to visualize shearing efficiency.
Note: five, seven, and 10 cycles gave fragments ranging
from 200–1,000 bp. In subsequent miniChIP experiments
with 10,000 cells, five cycles were used. Although seven and
10 cycles provided a good size range, there was risk of over
sonication and chromatin degradation using greater cycle
numbers. This image is also shown in supplemental Fig. 1.
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5.1.2 B. MiniChIPAssays Using qPCR and Promoter Tiling
Microarray Detection
This protocol is designed for 10,000 cells per ChIP
reaction. A single tube can be processed, starting with
the formaldehyde crosslinking of 10,000 cells with 0.1%
FA in 1 ml of DMEM + 10%FBS as described in
Materials and Methods. However, typical miniChIP
experiments comprise different antibody reactions. There-
fore, we have chosen to describe a method that allows for
three antibody conditions.
Formaldehyde crosslinking and cell lysis
1. Sort 30,000 cells into 1 ml of DMEM + 10%FBS into
an Eppendorf tube. This will allow for three antibody
reactions that each comprise 10,000 cells.
2. Add 2.7 μl of 37% formaldehyde (0.1% final concen-
tration) and invert tubes immediately two to three times
to ensure complete mixing. Incubate at room tempera-
ture for 10 min with occasional manual agitation.
3. Pellet cells by centrifuging at 2,500 rpm (300 rcf) for
10 min at 4°C.
4. Transfer tube to ice and remove supernatant.
5. Add 1 ml of ice-cold HBSS containing protease
inhibitor cocktail (HBSS+PIC), and invert the tube
three to four times to wash cells.
6. Pellet cells by centrifuging at 2,500 rpm (300 rcf) for
10 min at 4°C. Following centrifugation a tiny pellet
will be barely visible.
7. Transfer tube to ice and remove supernatant. At this
point, the cell pellet can be snap frozen on dry ice or
liquid nitrogen and stored indefinitely at −80°C.
8. For 30,000 cells, add 75 μl of Lysis buffer and 0.75 μl
of PIC (100× stock) such that each 10,000 cell
quantity will be lysed with 25 μl. Do not pipette up
and down, instead manually agitate the bottom of the
Eppendorf tube, and allow bubbles to form.
9. Incubate on ice for 5 min to ensure complete lysis.
10. Add 225 μl of HBSS+PIC to tube and mix by gently
inverting the tube four to six times and place back on
ice. If the SDS forms a white cloudy precipitate, place
the tube at room temperature for about 2–3 min and
mix by gently tapping the tube until precipitate
dissolves. Place directly on ice and proceed to step
11 immediately. It is important that aliquots are
prepared without SDS precipitation.
11. Aliquot 100 μl (25 μl lysis buffer + 75 μl HBSS+PIC
that contains 10,000 cell equivalents) of cell lysate
into three new Eppendorf tubes.
Sonication
1. Sonicate the samples for five cycles as described
above in Part A—Sonication Optimization. Perform
five cycles of sonication using the 30-s on/off cycle
setting.
2. Collect the soluble chromatin by centrifugation at
13,000 rpm (17,000 rcf) for 10 min at 4°C. Transfer
the supernatants to a single Eppendorf tube (300 μl),
while avoiding the small SDS pellets. Pooling of
supernatants following sonication eliminates shearing
variation and noise.
3. Add 330 μl (the extra 30 μl allows for the 10% input
control and pipetting error) of ice-cold 2× RIPA Buffer
(twofold dilution), and 6 μl of PIC (100× stock). Mix
by tube inversion three to four times. The final SDS
concentration will be ∼0.1%, which is suitable for
antibody immunoprecipitation.
4. Transfer 20 μl of the chromatin into a new Eppendorf
tube. This is used as the input chromatin control and
can be stored on ice until DNA purification.
Antibody immunoprecipitation
1. Aliquot 200 μl of the diluted chromatin into three new
Eppendorf tubes.
2. Add the antibodies. The amounts below were empiri-
cally determined in antibody titration experiments
(Figs. 2, S2, and S3). Two micrograms of normal
rabbit IgG provides a control for the 2 μg of anti-
H3K27me3 antibody and 0.25 μg of anti-H3K4me3
used in this experiment.
Tube 1. Anti-H3K4me3 (Abcam ab8580) 0.25 μg
(0.25 μl of 1 μg/μl stock)
Tube 2. Anti-H3K27me3 (Millipore 07-499) 2 μg
(2 μl of 1 μg/μl stock)
Tube 3. Normal Rabbit IgG (Millipore 12-370) 2 μg
(2 μl of 1 μg/μl stock)
3. Incubate for 2 h at 4°C (cold room) on a rotator device
with a setting of 200 rpm. This step can be carried out
up to 16 h depending on the efficiency of the antibody.
However, prolonged incubation times can increase non-
specific antibody binding and chromatin degradation,
and is therefore not encouraged.
Antibody–bead immunoprecipitation
1. For 3 miniChIP reactions, pipette 35 μl (the extra 5 μl
allows for pipetting error) of well-suspendedDynabeads®
protein A stock solution into a new Eppendorf tube on ice.
2. Add 200 μl of ice-cold 1× RIPA Buffer and mix well
by tapping the tube, place the tube in the magnetic
holder (placed directly onto ice), allow beads to be
captured, and remove the buffer with a pipette.
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3. Repeat the wash with another 200 μl of ice-cold 1×
RIPA buffer. Ensure the beads are fully resuspended
during this wash step.
4. Capture the beads on the magnet, remove the buffer,
and add a final volume of 35 μl of ice-cold 1× RIPA
buffer.
5. Add 10 μl of the Dynabeads® protein A to each tube.
Ensure that the beads remain resuspended by frequently
agitating the tube.
6. Incubate for 2 h at 4°C (cold room) on a rotator device
with a setting of 200 rpm.
Antibody–bead complex washes and elution
Washing of the antibody–beads complexes are per-
formed according to the method outlined by Dahl and
Collas [41]. Washes should be performed in a 4°C cold
room.
1. Centrifuge the tubes (2 s pulse) to remove sample
from the lid of tubes.
2. Place tubes onto chilled magnet rack (placed directly
onto ice), allowing beads to adhere and remove
supernatant.
3. Remove tubes from magnet rack, add 100 μl of ice-
cold 1× RIPA buffer. Gently tap tube to resuspend the
beads, and place onto rotator device.
4. Rotate tubes at 200 rpm for 4 min at 4°C.
5. Repeat steps 2. and 3. twice.
6. Centrifuge the tubes (2 s pulse), place them onto the
magnet rack and remove the supernatant.
7. Remove tubes from magnet rack and place on ice,
add 100 μl of ice-cold TE Buffer. Gently tap tube
to help resuspend the beads, and place onto rotator
device.
8. Rotate tubes at 200 rpm for 4 min at 4°C.
9. Centrifuge the tubes (2 s pulse), place onto the magnet
rack and remove the supernatant.
10. For complex elution, add 300 μl of Elution Buffer
(20 mM Tris pH 7.5/5 mM EDTA/50 mM NaCl/1%
SDS/50 µg/ml proteinase K) to the bead pellets and
incubate for 2–3 h at 65°C using a shaking Eppendorf
Thermomixer (1,300 rpm).
DNA purification
1. Briefly centrifuge tubes to remove sample from lid
and walls of the tube.
2. Place tubes onto the magnet rack and transfer the
supernatant containing the eluted complexes into new
tubes.
3. Add 300 μl of phenol/chloroform/isoamylalcohol and
mix by vortexing for ∼3 s.
4. Centrifuge samples for 10 min at 13,000 rpm
(17,000 rcf) at room temperature.
5. Transfer the upper aqueous phase (300 μl) into new a
tube.
6. Add 30 μl of 3 M sodium acetate (pH 5.2), 2 μl of
linear acrylamide (5 μg/μl stock) and 2 μl of glycogen
(5 μg/μl stock) to the supernatant, and mix by manual
agitation of tubes.
7. Add 800 μl of 97% ethanol (stored at −20°C). Mix
tubes by inversion four to six times and incubate for
∼16 h at −20°C or 1 h at −80°C.
8. Centrifuge the tubes at 13,000 rpm (17,000 rcf) for
20 min at 4°C to collect the precipitated DNA.
9. Remove the supernatant. Add 1 ml of 70% ethanol
(stored at −20°C) and invert the tubes four to six
times.
10. Centrifuge the tubes at 13,000 rpm (17,000 rcf) for
20 min at 4°C.
11. Remove the supernatant.
12. Air dry the DNA pellet and resuspend in 10 μl T10E0.1
(10 mM Tris–HCl pH 8.0, 0.1 mM EDTA pH 8.0)
buffer. Store the DNA samples at −20°C.
Real-time quantitative PCR analysis
The low concentration of DNA recovered from mini-
ChIP reactions with 10,000 cells allows for qPCR analysis
of ∼8 genomic regions to be performed in triplicate qPCR
reactions. Therefore, this assay provides enough DNA for a
total of 24 individual qPCR reactions.
The individual qPCR reaction volumes are 20 μl, and
two different master mixes are prepared. The ChIP DNA
mastermix is added to 96-well PCR plates prior to the
SYBR green master mix in order to minimize cross
contamination.
1. ChIP DNA or input DNA master mix
(a) Thaw DNA samples on ice.
(b) Prepare the ChIP DNA or input master mixes by
adding 190 μl sterile milliQ water (mqH2O) to each of
the tubes containing 10 μl of DNA (200 μl total
volume), mix by manual agitation, and centrifuge
briefly (2 s pulse), and place on ice.
(c) Since the SYBR green mastermix will account for
12 μl in a 20 μl qPCR reaction volume (see below),
aliquot 8 μl of each DNA sample to respective wells in
a PCR 96-well plate. Therefore, in each final qPCR
reaction, ∼0.5 μl of the ChIP DNA sample will be
analyzed if 24 reactions are performed. There should
be 8 μl remaining to accommodate variations in
pipetting.
2. SYBR green/primer master mix
(a) Prepare SYBR green/primer master mixes for the
number of genomic regions analyzed. For 20 μl qPCR
reaction volumes, the mastermix will comprise SYBR
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Green Master Mix (2×) 10 μL, forward primer (10 mM
stock) 1 μL and reverse primer (10 mM stock) 1 μl.
(b) Aliquot 12 μl into appropriate wells that already
contain 8 μl of the ChIP or input DNA samples.
3. qPCR analysis
(a) Perform real-time PCR of the samples using a 40-cycle
program.
(b) Acquire the data using the real-time PCR data
acquisition program. Most programs require that you
manually adjust the threshold value to the linear range
of the real-time PCR curve. Keep this value constant
when directly comparing experiments.
(c) Export the data into Excel spreadsheets.
(d) Calculate the amount of precipitated DNA relative to
input as % (ChIP/total input)=2^[(Ct(ChIP)−Ct(in-
put)×DF)]×100%. At least three biological indepen-
dent miniChIP experiments should be analyzed in
triplicate qPCR reactions for each genomic region
investigated.
(e) The SYBR qPCR detection method is based on using
equally efficient primer sets. Prior testing of primer
sets on input DNA or genomic DNA in a standard
curve experiment is required. Similar Ct values should
be obtained across a concentration range of 0.1 ng to
20 ng DNA. Melting curve analysis should reveal the
presence of a single amplicon and the absence of
primer dimers.
Promoter tiling microarray analysis
1. Library preparation and quality control analysis
(a) Thaw miniChIP DNA or input DNA samples on ice.
(b) Transfer the DNA samples (10 μL) into 0.2 ml PCR
tubes.
(c) Conduct amplification of the DNA samples in 0.2 ml
PCR tubes with the WGA4 GenomePlex Whole
Genome Amplification Kit (Sigma Aldrich) according
to the manufacturer's instructions. Note that the cell
lysis and DNA fragmentation steps will be omitted and
the protocol will start at Step 6 in the WGA4
procedure. A matching number of input and ChIP
DNA samples are amplified to cover the number of
ChIP DNA samples on the arrays.
(d) Purify the amplified DNA using the QIAquick PCR
purification kit (Qiagen, catalogue #28104) according
to the manufacturer's instructions.
(e) Perform qualitative and quantitative assessment of the
amplified DNA samples using 1% agarose gels and
NanoDrop Spectrophotometer, respectively. Typically,
the WGA4 kit leads to the production of ∼10 μg of
DNA with an average size of 500–2,000 bp suitable
for processing on NimbleGen microarrays.
(f) Perform qPCR surveys of genomic regions with the
expected enrichments for the cell types and histone
modifications examined. An example is provided in [28].
2. Array processing
1. Submit the amplified ChIP samples to NimbleGen
Systems, Iceland for processing according to their
standard protocols. The facility will perform the labeling,
hybridization, and scanning using the HD2 Hx1 promoter
tiling arrays (HD 2.1 M array) that span −8.2 kb to +3 kb
around TSS of ∼24,000 annotated genes.
3. Array normalization
1. Apply within-array normalization to single arrays by
applying using the MA2C software [37, 38] or
equivalent within-array normalizations tools.
2. Apply quantile normalization to replicate arrays in
order to facilitate between-array comparability and use
the average value of each quantile as the final intensity
for corresponding probes.
4. Identification of bound regions
1. Combine replicate arrays by averaging the Log2
enrichment values of each probe within the set of
replicates.
2. Identify significantly enriched regions (peaks) using
the peak finding algorithms as provided by the
NimbleScan software according to NimbleGen stan-
dard protocols.
3. Annotate peaks with a false discovery rate ≤0.05 by
mapping them to the NCBI gene tracks using the
NimbleScan software and a range of 8.2 kb down-
stream to 3 kb upstream relative to each transcriptional
start site.
4. Enforce unique associations between peaks and TSSs
by linking each peak only to the most proximate TSS
present in the annotated 11.2 kb region.
5. Quality control analysis
Possible quality control analyses can include the following:
1. Confirm within array normalization by deriving MA
plots before and after normalization and check for
resolution of any dye-bias related variations observed
in the raw data.
2. Investigate the range of signals between replicates
using bars and whisker plots in order to validate the
quantile normalization step.
3. Validate the overall normalization strategy in terms of
comparability between replicates by generating scatter
plots and Pearson correlation coefficients for each pair
of replicates. Use a sufficient sized set of probes to
reduce biasing of the results.
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4. Perform peak finding for single arrays before and after
within array normalization as well as before and after
quantile normalization, and compare the total base pair
range occupied by peaks found with a FDR of ≤0.05
between the replicate arrays and different normalization
steps. Total range of enrichment should remain in a
comparable range for replicates and before and after
normalization. The resultant normalization should
result in a convergence of peak numbers between
replicate arrays. Outsiders could represent failed ChIP
assays or array processing.
5. Investigate distribution of peaks within the 11.2 kb
region by plotting histograms of number of peaks
against distance from TSS. Replicate should show
highly similar distribution patterns also comparable
with literature.
6. After mapping the peaks to gene tracks (e.g., NCBI),
estimate the percentage of genes found enriched for
each of the different histone modifications and refer to
literature to confirm range of occupancy.
7. Investigate individual gene loci and compare normal-
ized arrays and peaks to ChIP–qPCR results.
8. If gene expression data is included in the data,
validate expected function of histone modifications
(gene activating/silencing) using correlation analysis
of genes expression values, peaks scores or enriched
base pair range of promoters. Positive correlation
should be observed for activating histone modifica-
tion; silencing histone modifications should show a
negative correlation with gene expression.
ChIP assay buffers
1× RIPA Buffer (50 ml)
Final concentration: Volume of stock buffers:
10 mM Tris–HCl, pH 7.5 500 μl of 1 M
1 mM EDTA 100 μl of 0.5 M
1% Triton X-100 5 ml of 10%
0.1% SDS 500 μl of 10%
0.1% Nadeoxycholate 500 μl of 10%
100 mM NaCl 1 ml of 5 M
Water 42.4 ml
2× RIPA Buffer (50 ml)
20 mM Tris–HCl, pH 7.5 1 ml of 1 M
2 mM EDTA 200 μl of 0.5 M
2% Triton X-100 10 ml of 10%
0.1% SDS 500 μl of 10%
0.2% Nadeoxycholate 1 ml of 10%
200 mM NaCl 2 ml of 5 M
Water 35.3 ml
Lysis Buffer (10 ml)
50 mM Tris–HCl, pH 8.0 500 μl of 1 M
10 mM EDTA 200 μl of 0.5 M
1% SDS 1 ml of 10%
Water 8.3 ml
TE Buffer (50 ml)
10 mM Tris–HCl, pH 8.0 500 μl of 1 M
10 mM EDTA 1 ml of 0.5 M
Water 48.5 ml
Elution Buffer (50 ml)
20 mM Tris–HCl, pH 7.5 1 ml of 1 M
5 mM EDTA 500 μl of 0.5 M
50 mM NaCl 500 μl of 5 M
Water 48 ml
Containing 1% SDS and 50 μg/ml proteinase K prior to use
All buffers must be 0.2 uM filtered sterilized, and are based on [41]
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